Why can’t they issue a PR when DCVax-L is involved? Are they holding everything back for a post-approval PR blitz? And why dilute at these lower prices? you guys spend so much time and effort goes into research involving our product, management continues its usual pattern of maintaining silence while diluting the stock around $0.25. It feels like we’re just waiting… and waiting… and waiting—forever.
Market Data 
Markets 
AI
